HOUSTON, Texas, August 11, 2026
FibroBiologics, Inc. announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,691,147, covering methods and compositions that use fibroblasts to facilitate the engraftment, survival, and function of transplanted insulin-producing pancreatic islets. The patent, titled “Methods and Compositions for Treatment of Type 1 Diabetes Using Fibroblasts in Facilitation of Islet Engraftment,” represents an important intellectual property milestone for the clinical-stage biotechnology company as it advances technologies based on fibroblast cells and fibroblast-derived materials. The patented approach is intended to address one of the major challenges associated with pancreatic islet transplantation: the loss of transplanted cells during the critical period following implantation. FibroBiologics said the technology could potentially have applications beyond Type 1 diabetes, including other cell and tissue transplantation procedures.
Patent Targets Islet Survival and Engraftment
Pancreatic islet transplantation is a cell-based approach designed to restore endogenous insulin production by replacing insulin-producing cells lost through autoimmune destruction in people with Type 1 diabetes. However, broader adoption of the approach has been constrained by the limited availability of donor pancreases and the difficulty of maintaining transplanted islet viability after implantation. FibroBiologics’ newly issued patent addresses this challenge by describing methods that incorporate fibroblasts to improve the microenvironment surrounding transplanted islets. Fibroblasts can produce extracellular matrix proteins, angiogenic factors, and trophic signals that may support vascularization, reduce cellular stress, and promote tissue survival. By improving the environment in which transplanted islets establish themselves, the technology is intended to enhance islet engraftment and long-term function.
Fibroblast Technology Could Improve Donor Tissue Use
The potential significance of the patented technology extends beyond improving individual transplantation outcomes. According to FibroBiologics, enhancing the survival and integration of transplanted islets could potentially increase the efficiency of donor tissue utilization. If a smaller quantity of islet tissue could achieve a therapeutic effect because more transplanted cells survive, the same limited donor supply could potentially be used to treat a greater number of patients. This could be particularly important for Type 1 diabetes, where the availability of donor pancreatic tissue remains a major limitation for cell transplantation approaches. The company believes fibroblasts may have important biological functions beyond their traditional structural role, including supporting tissue regeneration and cellular repair.
Advertisement
Broader Applications Across Cell Therapy
FibroBiologics said the patent may have applications beyond diabetes and could potentially support the development of technologies for other cell and tissue transplantation procedures. The company is developing a broader pipeline based on fibroblasts and fibroblast-derived materials for chronic diseases and regenerative medicine. Its intellectual property portfolio includes more than 270 issued and pending patents across areas such as wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, longevity, and cancer. The new U.S. patent adds further intellectual property protection around the company’s work in cell therapy and tissue regeneration, while highlighting the potential role of fibroblast-based approaches in improving the survival of transplanted therapeutic cells.
The company’s patent milestone comes as researchers and biotechnology developers continue exploring ways to improve the durability and scalability of cell-based therapies. For Type 1 diabetes, technologies that can increase the survival and function of transplanted insulin-producing cells could potentially address important limitations associated with current transplantation strategies. FibroBiologics emphasized that the newly issued patent provides intellectual property coverage for its fibroblast-based approach, while the potential clinical benefits and applications remain subject to further research and development. The patent strengthens FibroBiologics’ position in regenerative medicine and supports continued investigation of fibroblast-based technologies for improving cell and tissue transplantation.
Source: FibroBiologics press release
